BDMS invests THB 170 million to take majority stake: what it means for BDMS stock

Published on 10/20/2026 at 03:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts forecast Q3 net profit at THB 4.60 billion, up 8.00 percent year over year. A 55 percent GNPT stake adds a precision medicine angle for BDMS stock.

Precision medicine takes a larger role

BDMS agreed to invest THB 170 million in Genepeutic Bio on October 16, 2026.
Royal Bangkok Healthcare will raise its GNPT stake from 19.9 percent to 55 percent.
BDMS posted Q2 2026 net profit growth of 5.78 percent year over year.

BDMS, TH0264A10Z04, Illustration mit AI erstellt.

Bangkok Dusit Medical Services (TH0264A10Z04) agreed on October 16, 2026, to invest THB 170 million in Genepeutic Bio through its wholly owned subsidiary Royal Bangkok Healthcare, according to Kaohoon International. The deal will lift Royal Bangkok Healthcare's holding from 19.9 percent to 55 percent and make Genepeutic Bio a BDMS subsidiary.

What changes for precision medicine?

Genepeutic Bio researches and manufactures advanced therapy medicinal products, including cell and gene therapies. Nation Thailand reported on October 19, 2026, that the investment supports locally developed CAR-T cancer treatment, production expansion and further research.

The strategic value is tied to capacity as well as ownership. Genepeutic Bio can currently produce treatments for 40 patients annually, while additional equipment could raise capacity to 200 patients, according to Nation Thailand. The group also requires a separate service license before the treatment can launch at its hospitals, with the company targeting approval by the end of 2026.

Q3 estimates raise the earnings bar

The investment arrives as analysts expect a stronger third quarter. A brokerage roundup published by efinanceThai on October 14, 2026, put forecast net profit in a THB 4.55 billion to THB 5.08 billion range, with expected year-over-year growth of 5.40 percent to 17.70 percent. The same roundup placed hospital revenue between THB 29.30 billion and THB 29.37 billion.

BDMS's reported second-quarter picture provides the comparison point. Revenue growth was 4.84 percent year over year and net profit growth was 5.78 percent, while net profit margin stood at 14.57 percent, according to efinanceThai. For investors, the key question is whether hospital demand can fund a larger role in advanced therapies without weakening the core operating business.

Stock context and company profile

BDMS is listed on the Stock Exchange of Thailand under ticker BDMS and operates private hospital networks in Thailand and Cambodia. The company is included in the SET50, SET100, SETWB and SET ESG indexes, according to the company's investor-relations overview. Its latest reported Q2 2026 net profit margin of 14.57 percent gives the new biotechnology exposure a clear financial benchmark.